4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Atherosclerotic Parkinsonism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, X; He, Z; Hu, L; Hua, L; Li, M; Liu, J; Yan, J | 1 |
| Charlton, C; King, JM; Mackey, V; Muthian, G; Smith, M | 1 |
2 other study(ies) available for 4-phenyl-1,2,3,6-tetrahydropyridine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
MiR-302b-5p enhances the neuroprotective effect of IGF-1 in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease by regulating inducible nitric-oxide synthase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Humans; Insulin-Like Growth Factor I; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neuroprotective Agents; Nitric Oxide Synthase Type II; Parkinson Disease, Secondary | 2020 |
L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Female; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 2011 |